Eberconazole

Base Information

• Chemical Name: Eberconazole
• CAS No.: 128326-82-9
• Molecular Formula: C₁₈H₁₄Cl₂N₂
• Molecular Weight: 329.229
• UNII: V7O1U41C9B
• DSSTox Substance ID: DTXSID90926104
• Nikkaji Number: J561.862B
• Wikipedia: Eberconazole
• Wikidata: Q27156976
• NCI Thesaurus Code: C72961
• Metabolomics Workbench ID: 154445
• ChEMBL ID: CHEMBL558722
• Mol file: 128326-82-9.mol

Synonyms:1-(2,4-dichloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-1H-imidazole;eberconazole

Chemical Property of Eberconazole

Chemical Property:

• Vapor Pressure: 1.86E-09mmHg at 25°C
• Boiling Point: 495°Cat760mmHg
• PKA: 5.84±0.10(Predicted)
• Flash Point: 253.2°C
• PSA: 17.82000
• Density: 1.35g/cm³
• LogP: 4.92620
• XLogP3: 4.9
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 1
• Rotatable Bond Count: 1
• Exact Mass: 328.0534038
• Heavy Atom Count: 22
• Complexity: 391

Purity/Quality:

98%Min ^*data from raw suppliers

(+/-)-1-(2,4-DICHLORO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)IMIDAZOLE 95.00% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1CC2=C(C(C3=CC=CC=C31)N4C=CN=C4)C(=CC(=C2)Cl)Cl
• Recent EU Clinical Trials: Ensayo clínico multicéntrico, aleatorizado, paralelo, doble ciego, para evaluar la eficacia y seguridad de eberconazol solución 1% frente a placebo en el tratamiento de las dermatofitosis
• Description: Eberconazole is a new member of the azole class of antifungal agents, and it is indicated for the topical treatment of cutaneous fungal infections, including tinea corporis (ringworm of the body), tinea cruris (ringworm of the groin) and tinea pedis (athlete’s foot) infections. Its mode of action is similar to that of other azole antifungals, namely inhibition of fungal lanosterol 14α-demethylase. Eberconazole exhibits good in vitro activity against a wide range of Candida species, including Candida. tropicalis, dermatophytes and Malassezia spp. yeasts. It shows good activity against Candida. Parapsilosis (MIC90=0.125 mg/mL), which is a relevant species in skin and nail disorders. In addition, eberconazole is effective against some of the highly triazole-resistant yeasts such as Candida. glabrata and Candida. krusei, as well as fluconazole-resistant Candida. albicans. However, eberconazole is less active than clotrimazole and ketoconazole against Candida. neoformans and a number of clinically relevant molds. Eberconazole is supplied as a 1% or 2% cream, and the topical application does not result in detectable serum, urine, or fecal levels. In a phase II study of 60 patients with tinea corporis and tinea cruris, treatment with topical eberconazole (1% or 2% cream), applied once or twice daily for 6 weeks, resulted in cure rates ranging from 73.3–93.3% at the end of therapy, and 66.7–100% six weeks post-therapy.
• Uses: Eberconazole can be used for a novel antifungal formulation.

Technology Process of Eberconazole

There total 1 articles about Eberconazole which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ eberconazole (128326-82-9)

Guidance literature:

DOI:10.1128/aac.43.5.1258

Refernces